Chroma Therapeutics

16 articles about Chroma Therapeutics

• Viracta Therapeutics Acquires Phase II Epigenetic Drug Candidate From Chroma Therapeutics

  11/30/2016

• Chroma Therapeutics Release: Tosedostat Opal Study in Acute Myeloid Leukemia Published in Lancet Oncology

  3/4/2013

• Chroma Therapeutics Extends Collaboration With GlaxoSmithKline and Advances Novel Targeted Agent Towards Clinical Development; Receives Milestone Payment

  1/3/2013

• Cell Therapeutics, Inc. and Chroma Therapeutics Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML)

  12/13/2011

• Chroma Therapeutics and Cell Therapeutics, Inc. Announce New Positive Interim Phase II Data for Tosedostat in AML OPAL Study, Revealed at American Society of Clinical Oncology

  6/8/2011

• Chroma Therapeutics Release: New Tosedostat Data Selected for Oral Discussion Session at the 2011 American Society of Clinical Oncology Annual Meeting

  5/25/2011

• Cell Therapeutics, Inc. Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers

  3/14/2011

• Chroma Therapeutics to Present at 29th Annual J.P. Morgan Healthcare Conference

  1/6/2011

• Chroma Therapeutics Advances Novel Targeted Agent into Development; Receives Milestone Payment from GlaxoSmithKline

  8/24/2010

• GlaxoSmithKline Signs Potential $1 Billion Drug Deal with Chroma Therapeutics

  6/24/2009

• Invitrogen Corporation and Chroma Therapeutics Extend Kinase Screening Partnership

  2/25/2008

• Chroma Therapeutics Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797

  12/13/2007

• Chroma Therapeutics to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797

  11/30/2007

• Chroma Therapeutics Progresses Novel Cancer Therapy CHR-2797 Into Phase II Solid Tumour Study; Presents Phase I Data at American Society of Clinical Oncology

  6/13/2007

• Chroma Therapeutics Progresses Novel Cancer Therapy Into Phase II Clinical Development

  3/26/2007

• Chroma Therapeutics Raises $18.1M In Series B Financing

  6/15/2004